

Supplementary Table 4. Associations of *UGT1A* genotypes with treatment response

| | Responders ^a | | | | | |
|--------------------------------|-------------------------|---------|-------------------------|---------|---------------------------|---------|
| | Total patients (n = 91) | | Weekly regimen (n = 46) | | Biweekly regimen (n = 45) | |
| | No. (%) | p-value | No. (%) | p-value | No. (%) | p-value |
| <i>UGT1A1</i> *6 | | 0.493 | | 0.444 | | 0.35 |
| w (-/-) | 9/58 (15.52) | | 7/32 (21.88) | | 2/26 (7.70) | |
| m (-/+, +/+) | 7/33 (21.21) | | 4/14 (28.57) | | 3/19 (15.79) | |
| <i>UGT1A1</i> *27 ^b | | 0.504 | | 0.575 | | 0.76 |
| w (-/-) | 16/85 (18.82) | | 11/44 (25.00) | | 5/41 (12.20) | |
| m (-/+, +/+) | 0/2 (0.00) | | 0/0 (0.00) | | 0/2 (0.00) | |
| <i>UGT1A1</i> *28 | | 0.582 | | 0.601 | | 0.596 |
| w (6/6) | 12/67 (17.91) | | 8/34 (23.53) | | 4/33 (12.12) | |
| m (6/7, 7/7) | 4/24 (16.67) | | 3/12 (25.00) | | 1/12 (8.33) | |
| <i>UGT1A1</i> *60 | | 0.337 | | 0.245 | | 0.565 |
| w (-/-) | 9/44 (20.45) | | 7/23 (30.43) | | 2/21 (9.52) | |
| m (-/+, +/+) | 7/47 (14.89) | | 4/23 (17.39) | | 3/24 (12.5) | |
| <i>UGT1A7</i> | | 0.564 | | 0.54 | | 0.544 |
| *1/*1 | 3/27 (11.11) | | 3/19 (15.79) | | 0/8 (0.00) | |
| *1/*2, *2/*2 | 5/21 (23.81) | | 3/11 (27.27) | | 2/15 (13.33) | |
| *1/*3, *2/*3, *3/*3 | 8/38 (21.05) | | 5/16 (31.25) | | 3/22 (13.63) | |
| <i>UGT1A9</i> *22 | | 0.173 | | 0.234 | | 0.266 |
| w (10/10) | 3/29 (10.34) | | 3/19 (15.79) | | 0/10 (0.00) | |
| m (9/10, 9/9) | 13/62 (20.97) | | 8/27 (29.63) | | 5/35 (14.29) | |

Out of 91 assessable patients, 16 (17.6%) were considered responders. There were no associations between any *UGT1A* polymorphism and treatment response to irinotecan-containing chemotherapy.

^a Responder: complete or partial response, according to the guidelines of the Response Evaluation Criteria in Solid Tumors (RECIST) Committee.

^b Eighty-seven of 91 patients were analyzed for *UGT1A1**27 mutations.